Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medivation Slapped With Partial Hold Following PD-1 Confusion

This article was originally published in Scrip

Executive Summary

Medivation's share price dipped slightly on news that the US FDA has put a partial clinical hold on the IND for the anticancer pidilizumab (MDV9300). The decision by the regulatory agency was made after Medivation disclosed that the mechanism of action of pidilizumab was not via PD-1 inhibition, and work was "underway" to determine exactly what the mechanism is.

You may also be interested in...



With Medivation, Pfizer Sees A Chance For More Combinations

Most of the $14bn value Pfizer agreed to pay to buy Medivation is tied to future growth of Xtandi, according to the company, but two pipeline assets and the potential to combine drugs could offer upside.

Medivation Rejects Sanofi's Latest Bid, But Enters Confidential Negotiations

After two months of public, hostile back-and-forth, Sanofi agreed to confidentially discuss a potential acquisition of Medivation, putting the French pharma on equal footing with the biotech company's other suitors.

UK Reimbursement Decisions Focus Mostly On Cancer

The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.

Topics

Latest News
UsernamePublicRestriction

Register

SC064309

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel